User banner image
User avatar
  • admin

Posts

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that...

Cicada Resort Bali Ubud, Autograph Collection Welcomes Travelers for a Romantic Getaway in the Heart of Ubud’s Natural Beauty

BALI, Indonesia, Dec. 9, 2024 /PRNewswire/ — Located in Sebatu’s serene natural sanctuary, Cicada Resort Bali Ubud, Autograph Collection marks a new chapter in the...

State Grid Kizilsu Kirghiz Autonomous Prefecture Electric Power Supply Company: Power Visit to Promote Development, Be a Good Enterprise “Electric Housekeeper”

ARTUSH, China, Dec. 9, 2024 /PRNewswire/ — Recently, in order to ensure the safety and reliability of enterprise electricity during the season, the State Grid Kizilsu...

Noah Showcases Global Expansion and Investment Product Leadership at 2024 Corporate Open Day

Accelerating global expansion into emerging markets with new brands Global investment allocation strategies and expanded product offerings drive long-term value for clients Expanding comprehensive service...

After Two Red Dot awards: Creality’s K1 Series, HALOT-MAGE Pro and Falcon2 40W Named Finalists in IDEA 2024

AUSTIN, Texas, Dec. 9, 2024 /PRNewswire/ — Creality has proudly had its K1 Series 3D printers, HALOT-MAGE Pro 3D printer, and Falcon2 40W laser engraver...

Kwoon Chung Smart Mobility, Hong Kong Cyberport, and EHang Sign MOU

Promoting Autonomous Flight Technology, Establishing Industry Safety Standards, and Boosting Low-altitude Economic Development HONG KONG, Dec. 9, 2024 /PRNewswire/ — Kwoon Chung Bus Holdings Limited...

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3...

TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM,...

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent...

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP...